Amgen Inc (AMGN) Stock Rating

Amgen is a biotechnology company developing human therapeutics. Its main products include the red blood cell boosters Epogen and Aranesp, the immune boosters Neupogen and Neulasta, Enbrel and Otezla for inflammatory diseases, the bone drugs Prolia/Xgeva (approved 2010) and Evenity (2019), and its first cancer therapy Vectibix (introduced 2006). The Onyx Pharmaceuticals acquisition added the oncology drug Kyprolis.

Rating as of 2026-07-07. Live price updates in real time.